<DOC>
	<DOCNO>NCT02423005</DOCNO>
	<brief_summary>A prospective , randomise , control , single-blind , multi-site clinical study employ Neuromuscular Electrical Stimulation ( NMES ) stimulate pelvic floor muscle woman suffer stress urinary incontinence . Approximately one-hundred eighty ( 180 ) female patient diagnose stress urinary incontinence enrol study . All patient consider eligible participate clinical study give consent randomise complete either 12-week treatment programme Neurotech Vital Compact device 12-week treatment programme itouch Sure Pelvic Floor Exerciser . The 12-week treatment programme complete subject home treatment device accordance device Instructions Use .</brief_summary>
	<brief_title>Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US</brief_title>
	<detailed_description>This prospective , randomise , control , single-blind , multi-site clinical study conduct United States America ( USA ) employ Neuromuscular Electrical Stimulation ( NMES ) stimulate pelvic floor muscle woman suffer stress urinary incontinence . Approximately one-hundred eighty ( 180 ) female patient diagnose stress urinary incontinence enrol study . All patient consider eligible participate clinical study give consent randomise complete either 12-week treatment programme Neurotech Vital Compact device 12-week treatment programme itouch Sure Pelvic Floor Exerciser . The 12-week treatment programme complete subject home treatment device accordance device Instructions Use . Subjects include clinical study evaluate screening , enrolment study ( baseline ) 12-week treatment programme 4 12 week . A telephone call make 1 week check patient 's progress . In addition , subject evaluate 26 week follow commencement treatment .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>1 . Subjects female least 18 year age , 65 year age . 2 . Subjects sign informed consent form prior study related activity . 3 . Subjects previously try failed improve condition use Kegel exercise . 4 . Subjects clinically diagnose stress urinary incontinence demonstrate great equal 3g urine leakage less equal 90g urine leakage ( &gt; 3g &lt; 90g ) follow bladderfilling protocol standardise stress test ( provocative pad weight test ) baseline assessment . 5 . Subjects score 9 less ( &lt; 9 ) 18 Urge Incontinence Questions confirm predominant stress urinary incontinence Medical , Epidemiologic Social Aspects Aging Urinary Incontinence ( MESA ) Questionnaire complete screen assessment . 6 . Subjects Body Mass Index â‰¤ 35 kg/m2 . 7 . Subjects childbearing potential use highly effective contraceptive method ( establish use oral , injected , implanted hormonal method contraception barrier method contraception spermicide ) . 8 . Subjects willing seek treatment stress incontinence study period . 9 . Subjects able give voluntary , write informed consent participate study consent obtain . 10 . Subjects able understand study willing complete study assessment . 1 . Subjects exist medical condition would compromise participation study , e.g . reduce sensory perception contact area stimulation electrode ; scar vaginal tissue wound , lesion inflamed/infected area contact area stimulation electrode ; vaginal bleeding menstrual period ; uncontrolled diabetes . 2 . Subjects physical condition would make unable perform study procedure , e.g . pelvic hip surgery within past 6 week . 3 . Subjects diagnose Chronic Obstructive Pulmonary Disease ( COPD ) . 4 . Subjects history underlie neurological condition , e.g . Multiple Sclerosis , Parkinson 's disease , epilepsy . 5 . Subjects bladder abnormality would affect urinary flow lower urinary tract include sign symptom active urinary tract infection , abnormal bladder capacity ( e.g. , &gt; 300 cc ) , post void residual volume &gt; 200 cc , spastic bladder , vesicoureteral reflux bladder stone . 6 . Subjects blood clot disorder take anticoagulant medication . 7 . Subjects previously urogynaecological relate surgery would affect pelvic floor muscle urinary flow urethra ( exclude hysterectomy ) . 8 . Subjects previously pelvic floor radiation . 9 . Subjects previously treat stress incontinence injectable bulking agent and/or vaginal probe within past 6 month . 10 . Subjects clinical diagnosis prolapse great Stage 2 . 11 . Subjects pregnant could pregnant . 12 . Subjects less 6 month postpartum lactate . 13 . Subjects conductive intrauterine device metal implant pelvic area , include hip lumbar spine . 14 . Subjects pelvic pain fibromyalgia paravaginal defect . 15 . Subjects active implanted medical device ( i.e . pacemaker , insulin pump etc . ) condition may adversely affected electrical stimulation ( e.g . cardiac arrhythmia ) . 16 . Subjects current active history pelvic cancer and/or subject life expectancy le 12 month . 17 . Subjects currently involved injury litigation claim . 18 . Subjects participate clinical study last 3 month previous clinical study BioMedical Research Ltd. 19 . Subjects committed institution virtue order issue either court authority .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stress urinary incontinence</keyword>
	<keyword>Neurotech Vital Compact</keyword>
	<keyword>1h Provacative Pad Test</keyword>
	<keyword>Neuroelectrical Muscle Stimulation ( NEMS )</keyword>
</DOC>